{"type":"trials","record":{"id":42124,"source_id":"clinicaltrials-gov","external_id":"NCT03290794","title":"Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice","brief_summary":"The proposed regulatory post-marketing surveillance (PMS) study will be planned to collect the safety data of aflibercept intravitreal injection in patients with wet Age-related Macular Degeneration (AMD) in real-life treatment practice The primary objective is: \\- To collect safety data in wet AMD patients treated with intravitreal aflibercept injection The secondary objective is: \\- To determine how disease activity is monitored including type and frequency of ocular tests and frequency of injections","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Bayer","enrollment":100,"countries":["India"],"start_date":"2019-02-14","completion_date":"2023-05-26","last_update_date":"2023-06-09","source_url":"https://clinicaltrials.gov/study/NCT03290794","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Bayer","interventions":["Aflibercept (Eylea, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Frequency of reported ocular and non-ocular adverse events during observation period — Up to 6 months","Percentage of reported ocular and non-ocular adverse events during observation period — Up to 6 months","Type of ocular tests undertaken — Up to 6 months","Interval between ocular test — Up to 6 months","Date of aflibercept injections — Up to 6 months","Injection dose — Up to 6 months","Interval (days) between aflibercept injections — Up to 6 months","Frequency of monitoring / clinic visits — Up to 6 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Aflibercept (Eylea, BAY86-5321)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03290794","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-02-14 to 2023-05-26","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.923Z","intervention":["Aflibercept (Eylea, BAY86-5321)"],"participants":100,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Frequency of reported ocular and non-ocular adverse events during observation period — Up to 6 months","Percentage of reported ocular and non-ocular adverse events during observation period — Up to 6 months","Type of ocular tests undertaken — Up to 6 months","Interval between ocular test — Up to 6 months","Date of aflibercept injections — Up to 6 months","Injection dose — Up to 6 months","Interval (days) between aflibercept injections — Up to 6 months","Frequency of monitoring / clinic visits — Up to 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42124","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}